AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

DEXAMETHASONE SODIUM PHOSPHATE USP

7 registrations across 4 African markets— 6 active

Markets with DEXAMETHASONE SODIUM PHOSPHATE USP

Recent registrations

Brand / ProductMarketHolderStatusExpires
LILIDEXA INJECTION🇬🇭GhanaactiveJul 2030
LILIDEXA INJECTION🇬🇭GhanaactiveJul 2030
DEXAMED EYE/EAR DROPS
EYE/EAR DROPS
🇷🇼RwandaLABORATORY & ALLIED LTDactiveAug 2029
DEXAMETHASONE SODIUM PHOSPHATE OPHTHALMIC SOLUTION USP
Eye Drops
🇷🇼RwandaMERIT ORGANICS LTD.activeAug 2029
DEXO
Solution for injection
🇷🇼RwandaKILITCH DRUGS (INDIA) LTDactiveAug 2029
DEXNEO INJECTION
Injection
🇰🇪KenyaGALAXY PHARMACEUTICAL LTDactiveFeb 2028
DEXAMETHASONE 4MG/ML INJECTION
INJECTION
🇲🇼MalawiexpiredMar 2023

DEXAMETHASONE SODIUM PHOSPHATE USP in Africa — Regulatory Overview

DEXAMETHASONE SODIUM PHOSPHATE USP is registered across 4 African markets with 7 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Rwanda, Ghana, Kenya, Malawi. AfricaRegulatory refreshes this data daily from official government sources.

Of the 7 registrations, 6 (86%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.